Navigation Links
AEterna Zentaris Announces Completion of Phase 1 Study with Oral AEZS-112 in Cancer
Date:9/21/2009

ting GI problems, no clinically relevant drug-related adverse events or changes in laboratory safety parameters were observed.

"Prolonged courses of stable disease with minimal to no toxicity are encouraging signs", said Dr. Von Hoff. "The applications for an oral agent with these mechanisms of action are numerous."

Paul Blake, MD, AEterna Zentaris Senior Vice President and Chief Medical Officer added, "We are pleased with these Phase 1 results on AEZS-112, which indicate the potential for safe combination with other anticancer drugs. We now look forward to working on the further development of AEZS-112 in collaboration with our expert investigators."

About the AEZS-112 Phase 1 Study

This open-label, dose-escalation, multi-center, intermittent treatment Phase 1 study included patients with advanced solid tumors and lymphoma who had either failed standard therapy or for whom no standard therapy existed. Patients received a once-a-week oral administration of AEZS-112 for three consecutive weeks, followed by a one-week period without treatment. The cycles were repeated every four weeks based on tolerability and response, basically planned for up to four cycles, but allowing for continuation in case of potential benefit for the patient. The starting dose of AEZS-112 in this study was 13 mg/week, with doubling of doses in subsequent cohorts in the absence of significant toxicity. Primary endpoints of the Phase 1 trial focused on determining the safety and tolerability of AEZS-112 (maximum tolerated dose, MTD), as well as establishing a recommended Phase 2 dose and regimen. Secondary endpoints aimed at establishing the pharmacokinetics and determining the efficacy based on standard response criteria.

Preliminary results from this study were presented recently at the American Association for Cancer Research (AACR) Annual Meeting in Denver, Colorado. Poster #5567 entitled, "Phase I dose-escalation, safety, and pharma
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. AEterna Zentaris Partner, Keryx Biopharmaceuticals, Receives Orphan-Drug Designation for Perifosine (KRX-0401) for the Treatment of Multiple Myeloma
2. AEterna Zentaris to Present at Upcoming Rodman Renshaw Annual Global Investment Conference
3. AEterna Zentaris Announces Results from Two Phase 3 Studies with Cetrorelix in Benign Prostatic Hyperplasia
4. AEterna Zentaris Reports Second Quarter 2009 Financial and Operating Results
5. AEterna Zentaris to Present at Upcoming Canaccord Adams 29th Annual Global Growth Conference
6. AEterna Zentaris to Announce Second Quarter 2009 Financial and Operating Results on August 11, 2009
7. AEterna Zentaris Partner, Keryx, Announces Agreement with FDA on a Special Protocol Assessment for Phase 3 Trial with Perifosine (KRX-0401) for the Treatment of Multiple Myeloma
8. AEterna Zentaris: New Data Published on its Ghrelin Antagonist Compound, AEZS-123 (JMV2959), Supports its Use in Alcohol Addiction
9. AEterna Zentaris Receives US$10 Million from Institutional Investors
10. AEterna Zentaris to Report Data from Safety Study of Phase 3 Program in Benign Prostatic Hyperplasia with Cetrorelix Ahead of Schedule
11. AEterna Zentaris Opens Extended Study for Cetrorelix in Benign Prostatic Hyperplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... Opertech Bio, Inc., a company ... effective approach to sensory evaluation, today announced the ... U.S. Patent and Trademark Office, encompassing high-throughput sensory ... “Opertech’s taste evaluation technology called Microtiter Operant Gustometer ... system for rapid characterization of taste sensory properties,” ...
(Date:9/2/2014)... Inc. (TSXV: BRM) ("Biorem" or "the Company") today announced three ... large odour control systems for waste water treatment plants in ... consistent with the market resurgence in North America ... "After a difficult period of restraint in our core municipal ... growth. Our lower cost structure, technology improvements and supply chain ...
(Date:9/1/2014)... 2014 Reportlinker.com announces that a new ... India Solid Waste Management Vehicles Market ... http://www.reportlinker.com/p02350445/India-Solid-Waste-Management-Vehicles-Market-Forecast-and-Opportunities-2019.html In India ... bodies responsible for complete handling and regulation of ... around 135,000 MT solid waste is generated daily ...
(Date:8/31/2014)... (PRWEB) August 31, 2014 ... Industry” is a professional and in-depth research ... provides basic Polyacrylamide information, including Polyacrylamide definition, ... well as industry overview. This research covers ... as well as global industry analysis covering ...
Breaking Biology Technology:Opertech Bio Receives U.S. Patent for High-Throughput Taste Evaluation Technology 2India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 2India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 3India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 4India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 5India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 6India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 7India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 8International Polyacrylamide Industry & Copper Iodide Market Data Analysis Now Available at DeepResearchReports.com 2International Polyacrylamide Industry & Copper Iodide Market Data Analysis Now Available at DeepResearchReports.com 3
... In the quest to exploit unique properties at ... have developed a novel technique for creating uniform ... and students in the Department of Physics and ... methods from holographic lithography to demonstrate a new ...
... Pharmaceuticals, Inc. (NASDAQ: IDIX ), announced today that ... Stanley Global Healthcare Conference on September 13 at 8:35 a.m. ... the Bank of America Merrill Lynch Global Healthcare Conference on ... of America Merrill Lynch Financial Centre, London.   ...
... Cellectis (Alternext: ALCLS), the French genome engineering specialist, will present at ... September 20, 2011, and at the MidCap Event in Paris on ... will present the activities and the development strategy of the Cellectis ... Hyatt New York hotel on Tuesday, September 20, 2011 at 11:30 ...
Cached Biology Technology:Stevens researchers pioneer novel technique to make plasmonic nanogap arrays 2Stevens researchers pioneer novel technique to make plasmonic nanogap arrays 3
(Date:9/2/2014)... Field Museum will present the prestigious Parker/Gentry Award to ... to biodiversity conservation awareness. The Parker/Gentry Award is given ... team or organization whose efforts have had a significant ... whose actions can serve as a model to others. ... environmental science and conservation news website that draws more ...
(Date:9/2/2014)... of Human Genetics (ASHG) and the National Human ... Institutes of Health, have named Elizabeth P. Tuck, ... School in Columbus, Ohio, the first ASHG/NHGRI Genetics ... , The Genetics and Education Fellowship is intended ... experience, and network to prepare for a career ...
(Date:9/2/2014)... It,s not always true that digital distribution of ... by physical means, at least when file sizes ... study published in Yale,s Journal of Industrial ... of games for consoles such as PlayStation3. Researchers ... caused lower greenhouse gas emissions than game files ...
Breaking Biology News(10 mins):ASHG and NHGRI award first genetics and education fellowship 2
... The work of molecular biologist Joseph M. Miano, ... Miano helps head the Aab Cardiovascular Research Institute and ... and Pediatrics program at the University of Rochester Medical ... was highly unlikely, shared enthusiasm, intense curiosity and a ...
... of researchers from the University of Valladolid (Spain) has analysed ... free iron than pale and non-alcoholic beers. Iron is essential ... compounds that give these beverages stability and flavour. According ... (UVa) on 40 types of beers from all 5 continents, ...
... Scientists at the National Physical Laboratory (NPL) have mimicked ... genetic material. The research hopes to apply the approach ... defective genes such as those that cause cancer. ... challenges around targeting damaged cells and creating corrective genes. ...
Cached Biology News:In quest for new therapies, clinician-scientist team unlocks hidden information in human genome 2In quest for new therapies, clinician-scientist team unlocks hidden information in human genome 3In quest for new therapies, clinician-scientist team unlocks hidden information in human genome 4Dark beer has more iron than pale beer 2
... Agarose overlays are commonly used ... commercial "DNA grade" agaroses either ... to insect cells or lack ... obtain good overlays. Novagen's BacPlaque ...
AgarPlaque Plus Agarose 50 grams...
...
...
Biology Products: